Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy.
hepatoblastoma
neoadjuvant chemotherapy
nomogram
prognosis
systemic inflammation response index
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
08
2023
accepted:
02
10
2023
medline:
30
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
Inflammation is closely associated with tumor development and patient prognosis. The objective of this study is to assess the prognostic value of the preoperative inflammatory indexes in pediatric hepatoblastoma patients who receive neoadjuvant chemotherapy. A retrospective analysis was performed on clinical and pathological data of 199 hepatoblastoma patients who underwent hepatectomy with preoperative neoadjuvant chemotherapy from January 2015 to June 2020. The receiver operating characteristic curve was used to evaluate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) in predicting OS and EFS. Patients were grouped based on optimal cutoff values of preoperative inflammatory indexes. Survival rates were calculated using the Kaplan-Meier method, and survival outcomes were compared between groups using the log-rank test. Univariate and multivariate Cox proportional hazards regression models were used to identify independent prognostic factors, and a nomogram was constructed using R software to predict the probability of OS. The receiver operating characteristic curve showed prognostic value for OS, not EFS, in preoperative inflammatory indexes. Patients were categorized into low/high groups: SII ≤ 266.70/higher, NLR ≤ 1.24/higher, PLR ≤ 85.25/higher, and SIRI ≤ 0.72/higher. High NLR, PLR, SII, and SIRI groups had significantly lower 5-year OS than their low counterparts (all SIRI is an independent prognostic factor of hepatoblastoma patients receiving neoadjuvant chemotherapy. The OS nomogram based on SIRI, POSTTEXT staging, MiVI, and AFP can be used to assess the prognosis of those patients.
Identifiants
pubmed: 37901310
doi: 10.3389/fonc.2023.1276175
pmc: PMC10613067
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1276175Informations de copyright
Copyright © 2023 Zheng, Ye, Liu, Diao and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Rep. 2018 Mar 6;22(10):2541-2549
pubmed: 29514083
Cancer. 2003 Aug 15;98(4):668-78
pubmed: 12910509
Front Pediatr. 2023 Apr 12;11:904730
pubmed: 37124183
Medicine (Baltimore). 2022 Dec 2;101(48):e32022
pubmed: 36482636
J Investig Med. 2019 Mar;67(3):691-698
pubmed: 30127099
J Pediatr Surg. 2017 Sep;52(9):1496-1502
pubmed: 28188039
Lancet Oncol. 2019 May;20(5):719-727
pubmed: 30975630
J Autoimmun. 2019 Nov;104:102310
pubmed: 31421963
Cancer. 2011 May 1;117(9):1976-83
pubmed: 21509775
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
J Thorac Oncol. 2010 Sep;5(9):1315-6
pubmed: 20736804
Eur Radiol. 2009 Jan;19(1):209-19
pubmed: 18682957
Pediatr Blood Cancer. 2023 Jun;70 Suppl 4:e29965
pubmed: 36102690
Pediatr Int. 2018 Sep;60(9):862-868
pubmed: 29906299
Eur J Cancer. 2008 Mar;44(4):545-50
pubmed: 18166449
J Clin Oncol. 2000 Jul;18(14):2665-75
pubmed: 10894865
J Pediatr Surg. 2017 Jun;52(6):956-961
pubmed: 28347528
HPB (Oxford). 2013 Oct;15(10):741-6
pubmed: 23600968
Curr Opin Organ Transplant. 2019 Apr;24(2):113-117
pubmed: 30762666
Head Neck. 2020 Feb;42(2):336-343
pubmed: 31750591
Pediatr Radiol. 2007 Feb;37(2):123-32; quiz 249-50
pubmed: 17186233
J Allergy Clin Immunol. 2016 Oct;138(4):984-1010
pubmed: 27577879
Semin Immunol. 2018 Feb;35:12-18
pubmed: 29290545
J Clin Oncol. 2020 Aug 1;38(22):2488-2498
pubmed: 32421442
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Cancer Immunol Res. 2016 Feb;4(2):83-91
pubmed: 26839309
J Cancer Res Clin Oncol. 2017 Dec;143(12):2455-2468
pubmed: 28828692
J Cancer Res Clin Oncol. 2023 Aug;149(9):5627-5636
pubmed: 36520215
Lancet Oncol. 2017 Jan;18(1):122-131
pubmed: 27884679
Cell Death Dis. 2014 Nov 06;5:e1507
pubmed: 25375372
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6:e30576
pubmed: 37495540
Head Neck. 2022 Jun;44(6):1404-1413
pubmed: 35373866
J Clin Oncol. 2011 Aug 20;29(24):3301-6
pubmed: 21768450
Semin Pediatr Surg. 2019 Dec;28(6):150856
pubmed: 31931965
Front Mol Biosci. 2022 Feb 28;9:856064
pubmed: 35295846
Pediatr Radiol. 2018 Apr;48(4):536-554
pubmed: 29427028
J Clin Oncol. 2010 May 20;28(15):2584-90
pubmed: 20406943
Pharmacol Ther. 2016 Jan;157:112-9
pubmed: 26615781
Children (Basel). 2018 Dec 21;6(1):
pubmed: 30577683
Curr Opin Pediatr. 2014 Feb;26(1):29-36
pubmed: 24362406
Pediatr Blood Cancer. 2009 Dec;53(6):1016-22
pubmed: 19588519
Br J Cancer. 2010 Feb 16;102(4):639-44
pubmed: 20087353
Transplant Proc. 2019 Jun;51(5):1605-1610
pubmed: 31155201
J Pediatr Surg. 2012 Mar;47(3):e7-e12
pubmed: 22424376
Medicine (Baltimore). 2020 Dec 11;99(50):e23486
pubmed: 33327280
Nature. 2014 Nov 6;515(7525):130-3
pubmed: 25337873
J Pediatr Surg. 2017 Apr;52(4):618-624
pubmed: 28277300
Int J Clin Oncol. 2013 Dec;18(6):946-54
pubmed: 24136160
J Pediatr Surg. 2022 Oct;57(10):251-256
pubmed: 35810020
Cell Stem Cell. 2012 Dec 7;11(6):812-24
pubmed: 23168163
Eur Radiol. 2006 Jun;16(6):1393-6
pubmed: 16003511
Front Immunol. 2023 Mar 27;14:1118053
pubmed: 37051235
Methods Inf Med. 2015;54(2):198-9
pubmed: 25658987
Cancer. 2016 Jul 15;122(14):2158-67
pubmed: 27152949
Cancer. 2022 Mar 1;128(5):1057-1065
pubmed: 34762296
Children (Basel). 2023 Jan 22;10(2):
pubmed: 36832331
Ann Surg. 2017 Aug;266(2):318-323
pubmed: 27501172
J Clin Invest. 2013 Jul 1;:
pubmed: 23863628
Front Immunol. 2018 Jan 30;9:101
pubmed: 29441071
Dose Response. 2021 Dec 15;19(4):15593258211064744
pubmed: 34987341
Semin Pediatr Surg. 2005 Nov;14(4):233-8
pubmed: 16226698
Signal Transduct Target Ther. 2021 Jul 12;6(1):263
pubmed: 34248142
Clin Cancer Res. 2008 Nov 1;14(21):6735-41
pubmed: 18980965
Pediatr Blood Cancer. 2022 Dec;69(12):e29932
pubmed: 36031721
Cancer Lett. 2018 Apr 1;418:20-26
pubmed: 29306019
Mediators Inflamm. 2016;2016:6058147
pubmed: 26966341
Eur J Cancer. 2016 Jan;52:92-101
pubmed: 26655560
J Cancer Res Ther. 2022 Apr-Jun;18(3):677-680
pubmed: 35900540
Zhonghua Bing Li Xue Za Zhi. 2019 Mar 8;48(3):176-181
pubmed: 30831641
Pediatr Blood Cancer. 2023 Jun 7;:e30470
pubmed: 37283276
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249